

Venofer, Monoferic, or Fereheme

Protocol Types

Infusion Treatment 1, Infusion Treatment 2, Infusion Treatment 3, Infusion Treatment 4

Patient name: _____ DOB: _____

Please include: ☐ Patient face sheet ☐ Insurance authorization (if other than Medicaid or non-Advantage Medicare)

Diagnosis: _____

Review: Every 358 days

Orders

	Interval	Defer Until	Duration
Provider Communication			
☒ Provider communication	Once		1 treatment
Until discontinued Starting when released Until Specified			
Provider must order and obtain ferritin prior to patient being scheduled for iron infusion.			

This plan is intended for professional athletes. Per the World Anti-Doping Agency (WADA) Section M2.2: Infusion(s) must be restricted to 100 mL or less within a 12-hour period for both in-competitions and out-of-competitions.

Proceed with caution in patients with active systemic infection.

Pre-Procedure Labs

☐ Hemoglobin and hematocrit, blood	Once		1 treatment
Status: Once, Expected: S, Clinic Collect, Blood, Venous, Blood, AH INTERNAL LAB (BEAKER), Routine			
☐ Ferritin	Once		1 treatment
Status: Once, Expected: S, Clinic Collect, Blood, Venous, Blood, AH INTERNAL LAB (BEAKER), Routine			
☐ Iron + transferrin + TIBC	Once		1 treatment
Status: Once, Expected: S, Clinic Collect, Blood, Venous, Blood, AH INTERNAL LAB (BEAKER)			

Post-Procedure Labs

☐ Hemoglobin and hematocrit, blood	Once	S+42	1 treatment
Status: Once, Expected: S, Clinic Collect, Blood, Venous, Blood, AH INTERNAL LAB (BEAKER), Routine			
☐ Ferritin	Once	S+42	1 treatment
Status: Once, Expected: S, Clinic Collect, Blood, Venous, Blood, AH INTERNAL LAB (BEAKER), Routine			
☐ Iron + transferrin + TIBC	Once	S+42	1 treatment
Status: Once, Expected: S, Clinic Collect, Blood, Venous, Blood, AH INTERNAL LAB (BEAKER)			

Nursing Orders

☒ Treatment conditions	Every visit		Until discontinued
Until discontinued Starting when released Until Specified			
Hold treatment and notify provider if			
Ferritin GREATER THAN 300 ng/mL			
TSAT GREATER THAN 45%			
Temp GREATER THAN 38 C			
☒ Nursing communication	Every visit		Until discontinued

	Interval	Defer Until	Duration
Once Starting when released Instruct patient to set follow up appointment with provider for follow up labs.			
Therapeutic Medications			
☐ Venofer Orders			
☒ Nursing communication	3 times a week		5 treatments
Until discontinued Starting when released Until Specified Iron sucrose (Venofer) x 5 doses over 14 days.			
Monitor for hypersensitivity reaction for 30 minutes after each dose.			
☒ iron sucrose (Venofer) injection 200 mg	3 times a week		5 treatments
200 mg, intravenous, Administer over: 5 Minutes, Once, Starting when released IV push over 5 min. This plan is intended for professional athletes. Per the World Anti-Doping Agency (WADA) Section M2.2: Infusion(s) must be restricted to 100 mL or less within a 12-hour period for both in-competitions and out-of-competitions.			
☒ Infusion Appointment Request	3 times a week		5 treatments
Status: Once, Expected: S, Sched. Duration: 60 minutes, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after			
☐ MonoFerric Orders			
☒ Nursing communication	1 time a week		3 treatments
Until discontinued Starting when released Until Specified Ferric derisomaltose (MonoFerric) once weekly x 3 doses.			
Monitor for hypersensitivity reaction for 30 minutes after each dose.			
☒ ferric derisomaltose (MonoFerric) 500 mg in sodium chloride 0.9 % 105 mL IVPB	1 time a week		3 treatments
500 mg, intravenous, Administer over: 20 Minutes, Once, Starting when released This plan is intended for professional athletes. Per the World Anti-Doping Agency (WADA) Section M2.2: Infusion(s) must be restricted to 100 mL or less within a 12-hour period for both in-competitions and out-of-competitions.			
☒ Infusion Appointment Request	1 time a week		3 treatments
Status: Once, Expected: S, Sched. Duration: 60 minutes, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after			
☐ Fereheme Orders			
☒ Nursing communication	Every 3 days		2 treatments
Until discontinued Starting when released Until Specified Ferumoxytol (Fereheme) x 2 doses every 3 to 8 days.			
Monitor for hypersensitivity reaction for 30 minutes after each dose.			
☒ ferumoxytol (Feraheme) 510 mg in sodium chloride 0.9 % 67 mL IVPB	Every 3 days		2 treatments
510 mg, intravenous, Administer over: 15 Minutes, Once in dialysis, Starting when released			
☒ Infusion Appointment Request	Every 3 days		2 treatments
Status: Once, Expected: S, Sched. Duration: 60 minutes, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after			
Emergency Medications			
☒ Nursing communication	PRN		Until discontinued
STAT, Until discontinued Starting when released Until Specified If hypersensitivity reaction occurs, stop infusion IMMEDIATELY and CALL provider.			
☒ Vital Signs	PRN		Until discontinued
STAT, Every 15 min Starting when released If a hypersensitivity reaction occurs, perform vital signs every 15 minutes for one hour, then every 30 minutes for 2 hours.			

	Interval	Defer Until	Duration
☒ Nursing communication Once Starting when released If hypersensitivity reaction occurs: - Elevate head of bed 30 degrees and place patient's head at 30 degree angle if possible - Start 2 liters oxygen per nasal cannula and maintain airway - Change and maintain IV line with 1000 mL 0.9% Normal Saline	PRN		Until discontinued
☒ Nursing communication Until discontinued Starting when released Until Specified Avoid intravenous or oral diphenhydrAMINE, move to next option in the algorithm. Adverse effects of diphenhydrAMINE may overlap with IV iron adverse effects such as flushing, hypotension, tachycardia.	PRN		Until discontinued
☒ sodium chloride 0.9 % infusion 30 mL/hr, intravenous, Continuous PRN, KVO, Starting when released, for 1 day	PRN		Until discontinued
☒ sodium chloride 0.9 % bolus 500 mL, intravenous, Administer over: 30 Minutes, Once as needed, hypersensitivity or infusion reaction, Starting when released, Until Discontinued For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)	PRN		Until discontinued
☒ albuterol 2.5 mg /3 mL (0.083 %) nebulizer solution 2.5 mg 2.5 mg, nebulization, Every 4 hours PRN, Hypersensitivity reaction, Starting when released, for 1 day	PRN		Until discontinued
☒ albuterol HFA 90 mcg/act inhaler 2 puff 2 puff, inhalation, Every 4 hours PRN, Hypersensitivity reaction, Starting when released, for 1 day SHAKE WELL	PRN		Until discontinued
☒ acetaminophen (Tylenol) tablet 650 mg 650 mg, oral, Once as needed, fever, GREATER THAN or EQUAL TO 38 C, Starting when released, for 1 dose For mild/moderate reaction: flushing, rash, pruritus	PRN		Until discontinued
☒ famotidine (Pepcid) IV 20 mg 20 mg, intravenous, Administer over: 15 Minutes, Once as needed, dose for hypersensitivity or infusion reaction, Starting when released, for 1 dose	PRN		Until discontinued
☒ hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg 100 mg, intravenous, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose For mild/moderate reaction: flushing, rash, pruritus - OR - For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)	PRN		Until discontinued
☒ EPINEPHrine (EpiPen;Adrenalin) injection solution 0.3 mg 0.3 mg, intramuscular, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)	PRN		Until discontinued

*Provider signature

Provider printed name

*Date

Time

*Provider phone#

* Denotes field that must be completed by healthcare worker